Companies › Lycia Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LCA-0061 Antibody-based therapeutic designed to selectively bind and rapidly clear immunoglobulin E | IGHM | Phase 1 | Atopic Disease | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07701954 | LCA-0061 | Phase 1 | Atopic Disease | Immunology | Apr 2028 |
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.